Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

<p>– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals or immunomodulators alone – – Preclinical data suggest the […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/vir-biotechnology-presents-new-data-evaluating-the-potential-for-vir-2218-and-vir-3434-as-therapies-for-chronic-hepatitis-b-and-hepatitis-d/">Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>